# Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma

> **NCT00234026** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00234026
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** — (—)
- **Last updated:** 2012-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234026, "Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00234026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*